Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is VolitionRx Limited (VNRX) Stock Down -4.56% Today?

Why Is VolitionRx Limited (VNRX) Stock Down -4.56% Today?

Key Takeaways

  • VolitionRx Limited (VNRX) fell 4.56% to $0.1801 in intraday trading, down from the prior close of $0.1887.
  • No fresh company release, filing, or analyst action surfaced on the session; the decline extends a six-day unwind of the post-earnings spike that briefly lifted shares to $0.23.
  • Secondary pressure comes from dilution and balance-sheet optics: shares outstanding have roughly doubled over the past year, and the stock trades well below its recent moving averages.
  • Breadth context was mixed but far milder — the broader market slipped about 0.5%, biotech ETFs were roughly flat, and the move was almost entirely company-specific.
  • News Significance Score: 12/100 — Thin verified catalyst against a decline smaller than this stock's routine daily swing.
  • Volume is running below the recent daily pace, signaling an absence of conviction sellers rather than a fresh rush for the exits.
  • Traders are focused on the pending French reimbursement submission, publication of the feline lymphoma study and its $5 million milestone, and progress on licensing talks.
  • For deeper detail on VNRX, explore the dedicated Price Targets, Earnings, and Forecast pages.
  • Readers interested in systematic strategies can review the curated Trending AI Robots list for the strongest performing bots in current conditions.

Opening Summary

VolitionRx Limited (VNRX) is a Henderson, Nevada-based epigenetics company developing low-cost blood tests built on its Nu.Q platform, aimed at detecting and monitoring cancers and NETosis-related conditions such as sepsis, alongside a veterinary cancer franchise. Shares were quoted at $0.1801 on Wednesday, a decline of 4.56% from the previous session's close of $0.1887. The direction is unambiguously lower, but no single verified news event on the day explains the drop: the company's third-quarter results were released on November 12, and the current price action represents the continued fading of the sharp rally those results produced.

Post-Earnings Fade Drives the Session

The dominant force behind Wednesday's decline is the unwinding of the earnings-driven move from November 13, when VNRX jumped 24.7% to $0.2300 on roughly 57 million shares — many times its normal turnover — after third-quarter revenue of $1.61 million crushed a consensus near $706,000 and the quarterly net loss narrowed to about $3.8 million from $5.4 million a year earlier. That surge has been steadily reversed: shares fell 13.1% on November 16 and another 5.6% on November 17 before Wednesday's slide, leaving the stock roughly 22% below its post-earnings closing level. This pattern is consistent with short-term traders taking profits on a nano-cap spike rather than with a fresh deterioration in the business.

Dilution and Balance-Sheet Overhang

Underneath the earnings reaction sits a structural headwind that has weighed on the equity all year. Shares outstanding of roughly 36 million are more than double the year-earlier figure, and the company carries a market value of only about $6.6 million after a 52-week decline of roughly 97%. Management has made debt reduction a priority — retiring a $7.5 million convertible note in September and prepaying $500,000 against a $2.4 million note in October, leaving about $0.7 million outstanding — while the lender agreed to pause conversion rights until January 2027 unless the closing price reaches $0.275. Those steps reduce future dilution risk, but the very low share price keeps the conversion and capital-raising question in front of investors.

Market Context and Trading Activity

Wednesday's backdrop offered no sector-wide excuse. The S&P 500 proxy slipped about 0.5% and the iShares Biotechnology ETF (IBB) eased a similar amount, while the SPDR S&P Biotech ETF (XBI) was marginally higher, so small-cap biotech was essentially flat. Turnover in VNRX reached only about 1.1 million shares by late morning against a 20-day average near 4 million, confirming that the selling was thin rather than forceful. The stock traded a wide intraday band of roughly $0.170 to $0.185 and remains about 20% below its 50-day moving average near $0.226 and far beneath its 200-day line.

News Significance Score

The score runs from 0, meaning no meaningful news and a routine price move, to 100, meaning transformative news and an extreme, rare move. This event lands at 12 out of 100. The verified news backdrop is thin for the session itself: a quarterly beat and a debt-reduction program were disclosed days earlier and are modest in scale relative to a company with roughly $6.6 million in market value and no 2026 guidance.

The price behavior was equally unremarkable by this stock's standards. The 4.56% decline was only about 0.8 times the typical daily move of roughly 5.8%, and 28 of the prior 60 sessions produced an equal or larger swing. With neither a strong catalyst nor an anomalous move, the two factors combine into a low score.

What Comes Next for VNRX

The next scheduled financial update is not expected until the first quarter of 2027, leaving investors to trade on operational news flow in the interim. The most immediate items are the planned French reimbursement submission for the Nu.Q Lung Cancer test, publication of the peer-reviewed feline lymphoma study that would satisfy a condition for a $5 million milestone payment, and progress in licensing discussions with major diagnostics and liquid biopsy companies, including the Missionpharma letter of intent covering point-of-care sepsis triage. Four analysts currently carry a Buy consensus, though their views span an unusually wide range. Risks include continued cash burn, the possibility of further equity issuance, reliance on partner timelines, and the persistent sub-$1 price that constrains institutional participation.

Trending AI Robots

Tickeron operates a curated Trending AI Robots page that surfaces only the strongest performing automated strategies under present market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as conditions evolve. Investors looking for systematic approaches to volatile names may find it a useful starting point for further research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VNRX

Contributor

Dem Sem's AvatarDem Sem|Expert

VNRX's Stochastic Oscillator entering oversold zone

The Stochastic Oscillator for VNRX moved into oversold territory on November 18, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Oscillator exited the oversold zone, 27 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a development stage life sciences company

Industry MedicalNursingServices

Industry
Medical Or Nursing Services
Address
1489 West Warm Springs Road
Phone
+1 512 774-8930
Employees
75
Web
https://www.volition.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.